急性肾损伤治疗市场（按治疗类型、急性肾损伤类型、最终用户和患者人口统计）—全球预测，2025-2032 年

预计到 2032 年急性肾损伤治疗市场将成长至 37.5 亿美元，复合年增长率为 8.03%。

策略介绍，解释为什么急性肾损伤治疗重点需要协调的临床创新、诊断精确度和系统层级回应

急性肾衰竭是重症加护、肾臟病学以及更广泛的医院系统交叉领域面临的复杂临床挑战。近年来，人们越来越关注早期发现、治疗方法优化以及连接急诊、加护治疗和门诊追踪的综合护理路径。诊断技术的进步、体外治疗的逐步改进以及对药物治疗安全性的日益关注，正在改变临床决策和医疗保健提供者的工作流程。同时，人口结构的变化，例如人口老化和慢性併发症的增加，正在增加肾损伤风险患者的比例。

本简介阐述了驱动治疗选择和组织反应的核心动态。它强调了多学科协作的必要性、对更快、更准确的诊断讯号的需求，以及价值观对治疗方法选择和出院后管理日益增长的影响。透过将临床趋势置于卫生系统的优先事项（效率、病人安全和优化结果）之中，本刊头强调了为什么临床领导者、製造商和付款人必须围绕能够显着减轻急性肾损伤负担的创新展开合作，同时关注成本和供应链的现实情况。

技术创新、生物标记的进步以及不断发展的治疗模式如何改变急性肾损伤的治疗途径和结果

重塑急性肾损伤治疗的变革既基于技术，也基于系统。在技​​术方面，在加护治疗环境中采用连续性肾臟替代疗法 (CRT) 的同时，设备层面也得到了改进，从而提高了血流动力学耐受性，并促进了与即时监测系统的整合。同时，生物标记研究的进展使得更早的风险分层和更有针对性的干预措施成为可能，从而减少了对血清肌酸酐的单一依赖。这些技术变革得到了数位平台的增强，这些平台可以汇总生理数据并进行预测分析，从而识别即将面临风险的患者，并促进更早的临床回应。

从系统角度来看，医疗服务模式正变得更加分散，更多地利用门诊和专科诊所进行追踪和支持性管理。这一趋势虽然减轻了住院患者的负担，但也需要新的途径来确保医疗服务的连续性，尤其是对于那些从医院转入家中且仍有残留肾功能损害的患者。此外，抗生素管理计划、最大程度减少肾毒素暴露的通讯协定以及标准化的液体管理途径正在被纳入机构实践，从而改变了急性肾损伤的发生率和严重程度。总而言之，这些转变为能够提供涵盖急性期至急性后期诊断、治疗和服务解决方案的公司创造了跨部门合作和商业机会。

2025 年美国关税变化的预期累积效应可能会重塑急性肾损伤采购、供应链弹性和医疗服务

美国预计在2025年实施新的和修订的关税，这将引发一系列供应侧动态，可能对急性肾损伤的治疗提供产生重大影响。针对医疗设备、耗材或零件进口的关税措施可能会增加透析设备、过滤器和一次性耗材的购买成本。这些成本压力可能会导致采购商重新评估筹资策略，寻找替代供应商，重新协商合同，并可能延长资本密集型设备的使用寿命或推迟更换。此类调整可能会对医院系统内的临床排程、医疗模式可用性和资本规划产生下游影响。

除了直接的价格效应外，政策主导的贸易变化往往会加速在地化趋势。製造商和供应商可以透过重组供应链、将某些职能转移到国内或寻求关键医疗用品的关税分类或豁免来应对。虽然这些应对措施可以减少长期风险，但随着新的製造和分销安排的扩大，它们也会造成短期中断。同时，医疗保健提供者和卫生系统可能会加大力度，优化依赖在地采购药品和耗材的药物治疗和支持性护理的使用，以对冲进口供应波动。临床医生和采购团队需要合作，以确保医疗服务的连续性，同时应对价格和供应情况的变化。而积极沟通供应保证和替代采购的产业相关人员可能会在这项关税主导的转型中获得竞争优势。

关键细分洞察，将治疗方式、损伤病因、治疗环境和人口群体与精确的临床和商业性优先事项进行映射

有效的细分视​​角透过将治疗方式、损伤亚型、护理环境和患者群体联繫起来，明确临床需求和商业性重点。根据治疗类型，市场分为透析、药物治疗和支持性护理。透析进一步分析为持续性肾臟替代疗法、间歇性血液透析机及持续性低效透析。药物治疗着重于抗生素、利尿剂、止痛药和补液药物，而支持性护理则着重于饮食和液体管理。这种以治疗为导向的视角强调了特定于治疗方式的设备特性、耗材物流和药物安全计画必须与临床路径保持一致。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 整合人工智慧演算法早期发现住院病患急性肾损伤
• 新兴的生物标记指导的个人化治疗通讯协定，以降低外科患者急性肾损伤的风险
• 过渡到加护治疗环境中的照护现场诊断设备以快速评估肾功能
• 开发新的肾臟替代疗法，改善生物相容性并减少ICU护理併发症
• 增加对基于细胞的再生医学方法的投资，以修復移植后肾损伤的机制
• 扩展远距远端医疗病患监测平台，以便早期疗育急性肾损伤的管理
• SGLT2抑制剂在糖尿病患者肾臟保护和预防急性肾损伤的应用日益增多
• FDA 和 EMA 加速监管行动，授予创新 AKI 治疗候选药物突破性疗法认定

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章急性肾损伤治疗市场（依治疗类型）

• 透析
  • 连续性肾臟替代疗法（CRRT）
  • 间歇性血液透析机
  • 持续低效透析（SLED）
• 药物治疗
  • 抗生素
  • 利尿剂
  • 疼痛管理药物
  • 补液药物
• 支持性护理
  • 饮食管理
  • 体液管理

第九章急性肾损伤治疗市场-AKI类型

• 肾内源性急性肾损伤
• 肾后性急性肾损伤
• 肾前性急性肾损伤

第 10 章急性肾损伤治疗市场（依最终使用者）

• 门诊手术中心
• 医院
• 专科诊所

11. 急性肾损伤治疗市场（依患者人口统计）

• 成年患者
• 老年患者
• 儿科患者

第十二章急性肾损伤治疗市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章急性肾损伤治疗市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 急性肾损伤治疗市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Abbott Laboratories
  • Alloksys Life Sciences BV
  • Amgen Inc.
  • Asahi Kasei Medical Co., Ltd.
  • Astellas Pharma Inc.
  • B. Braun Melsungen AG
  • Baxter International, Inc.
  • Bayer AG
  • bioMerieux SA
  • CardioRenal Systems, Inc.

The Acute Kidney Injury Treatment Market is projected to grow by USD 3.75 billion at a CAGR of 8.03% by 2032.

A strategic introduction explaining why acute kidney injury treatment priorities demand coordinated clinical innovation, diagnostic precision, and systems-level responses

Acute kidney injury presents a complex clinical challenge at the intersection of critical care, nephrology, and broader hospital systems. Recent years have seen an intensification of focus on early detection, modality optimization, and integrated care pathways that connect emergency, intensive care, and outpatient follow-up. Advances in diagnostics, incremental improvements in extracorporeal therapy, and heightened attention to medication safety have altered clinical decision-making and provider workflows. At the same time, demographic shifts such as an aging population and rising prevalence of chronic comorbidities increase the proportion of patients at risk for renal insults, which in turn elevates pressure on hospitals and specialty clinics to adopt protocols that reduce progression and long-term morbidity.

This introduction frames the core dynamics driving treatment choices and organizational responses. It highlights the imperative for multidisciplinary coordination, the need for faster and more precise diagnostic signals, and the growing influence of value-based considerations on modality selection and post-discharge management. By situating clinical practice trends within health-system priorities-efficiency, patient safety, and outcome optimization-this opening underscores why clinical leaders, manufacturers, and payers must align around innovations that demonstrably reduce acute kidney injury burden while remaining attentive to cost and supply chain realities.

How technological innovations, biomarker advances, and evolving care models are jointly transforming acute kidney injury treatment pathways and outcomes

Shifts reshaping acute kidney injury care are both technological and systemic. On the technological front, the adoption of continuous renal replacement therapies in intensive care settings has been accompanied by device-level refinements that improve hemodynamic tolerance and facilitate integration with real-time monitoring systems. Parallel advances in biomarker research are enabling earlier risk stratification and more targeted intervention, reducing reliance on serum creatinine alone. These technical changes are reinforced by digital platforms that aggregate physiologic data, enabling predictive analytics to identify patients at imminent risk and prompting earlier clinical responses.

Systemically, care delivery models are moving toward decentralization and greater use of ambulatory and specialty clinic settings for follow-up and supportive management. This trend reduces inpatient burden while necessitating new pathways for continuity of care, particularly for patients who transition from hospital to home with residual kidney dysfunction. Additionally, antibiotic stewardship programs, protocols to minimize exposure to nephrotoxins, and standardized fluid management pathways are becoming embedded in institutional practice, altering the incidence and severity of acute kidney injury episodes. Taken together, these shifts create opportunities for cross-disciplinary collaboration and for companies that can deliver integrated diagnostic, therapeutic, and service solutions that span the acute-to-post-acute continuum.

Projected cumulative effects from United States tariff changes in 2025 that could reshape procurement, supply chain resilience, and treatment delivery for acute kidney injury

The prospect of new or modified tariffs in the United States in 2025 introduces a set of supply-side dynamics that can materially affect acute kidney injury treatment delivery. Tariff measures focused on medical devices, disposables, or component imports can increase acquisition costs for dialysis machines, filters, and single-use consumables, which are integral to both inpatient and ambulatory renal replacement therapy. Such cost pressures may drive purchasers to reassess procurement strategies and to explore alternative suppliers, contract renegotiation, and in some cases, extended use or deferred replacement of capital-intensive equipment. These adjustments can have downstream implications for clinical scheduling, modality availability, and capital planning within hospital systems.

Beyond direct price effects, policy-driven trade changes often accelerate localization trends. Manufacturers and suppliers may respond by reconfiguring supply chains, onshoring certain capabilities, or seeking tariff classifications and exemptions for critical medical goods. Such responses can reduce long-term exposure but also create short-term disruptions as new manufacturing or distribution arrangements scale. In parallel, providers and health systems will likely intensify efforts to optimize the use of pharmacological treatments and supportive care that rely on locally sourced medications and consumables, as a hedge against imported supply volatility. Clinicians and procurement teams will need to coordinate to ensure continuity of care while navigating pricing and availability changes, and industry players that proactively communicate about supply assurance and alternative sourcing will have a competitive advantage during any tariff-driven transition.

Key segmentation insights that map treatment modalities, injury etiologies, care settings, and demographic cohorts to precise clinical and commercial priorities

An effective segmentation lens clarifies clinical needs and commercial priorities by linking treatment modalities, injury subtypes, care settings, and patient cohorts. Based on treatment type, the market is studied across dialysis, pharmacological treatment, and supportive care where dialysis is further analyzed across continuous renal replacement therapy, intermittent hemodialysis, and sustained low-efficiency dialysis; pharmacological treatment considerations encompass antibiotics, diuretics, pain management drugs, and rehydration drugs; and supportive care focuses on dietary management and fluid management. This treatment-oriented view highlights how modality-specific device features, consumable logistics, and medication safety programs must align with the clinical pathway.

Based on AKI type, the analysis differentiates intrinsic renal acute kidney injury, post-renal acute kidney injury, and pre-renal acute kidney injury to surface diagnostic needs and targeted interventions that vary by etiology. Based on end user, the review segments ambulatory surgical centers, hospitals, and specialty clinics to show how engineering requirements, staffing models, and capital deployment differ across settings. Based on patient demographics, attention to adult patients, geriatric patients, and pediatric patients reveals nuances in dosing, device size, and follow-up intensity. Integrating these segmentation axes provides a multidimensional picture in which product design, clinical protocols, and service models must be calibrated to fit distinct combinations of modality, etiology, care setting, and patient age profile.

Regional perspectives on adoption, procurement, and capacity building across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence AKI care pathways

Regional dynamics shape how acute kidney injury treatment innovations are adopted, financed, and scaled. In the Americas, health systems emphasize hospital-based critical care capacity with a growing interest in ambulatory and home-based modalities to alleviate inpatient demand; procurement trends and payer arrangements in this region incentivize device interoperability and total-cost-of-care initiatives. Europe, Middle East & Africa displays heterogeneity, where some markets prioritize centralized specialist centers and others focus on expanding point-of-care capabilities; regulatory diversity across the region drives manufacturers to pursue modular product strategies and regionally tailored clinical evidence to support adoption. In the Asia-Pacific region, rapid expansion of hospital infrastructure, combined with a rising burden of chronic diseases and aging populations, creates strong demand for scalable dialysis solutions, while local manufacturing and regional supply chains influence procurement decisions.

These regional distinctions have implications for clinical protocols, distribution partnerships, and service models. Companies and health systems must tailor engagement strategies to each region's mix of inpatient capacity, outpatient growth, regulatory environment, and sourcing realities. Cross-border learning can accelerate adoption of best practices, but regional adaptation is essential to account for differences in workforce, reimbursement, and infrastructure maturity. Consequently, regional strategic planning should prioritize flexible product portfolios, adaptive pricing models, and investments in training that accommodate local care delivery patterns.

Critical company-level insights revealing how product innovation, diagnostics, and integrated service models are reshaping competitive advantage in AKI treatment ecosystems

Competitive dynamics in acute kidney injury treatment reflect an ecosystem of device manufacturers, pharmaceutical suppliers, diagnostics developers, and service providers. Device makers are investing in improved biocompatible materials, automated monitoring functions, and interfaces that support integration with electronic health records, while suppliers of consumables focus on supply reliability, sterilization quality, and cost-efficiency. Pharmaceutical companies are concentrating on stewardship programs, nephroprotective agents in development, and formulations that simplify dosing in heterogeneous patient populations. Diagnostic developers are advancing actionable biomarkers and point-of-care assays that shorten the time to intervention and enable risk-stratified treatment pathways.

Across this landscape, strategic moves such as alliances with hospital systems, bundled service offerings, and extended warranties are common as companies seek to reduce total cost of ownership for providers. There is also notable activity in after-sales service, remote monitoring, and training programs to ensure devices deliver consistent performance in high-acuity environments. Competitive advantage increasingly depends on the ability to present an integrated value proposition that couples technology with clinical evidence, service reliability, and clear pathways for reimbursement and implementation within complex care settings.

Actionable recommendations for healthcare leaders and industry stakeholders to enhance supply chain resilience, accelerate diagnostics, and secure reimbursement pathways

Industry leaders should take decisive steps to protect continuity of care while advancing innovation. Prioritize strengthening supply chain resilience by diversifying suppliers, reviewing tariff classifications, and evaluating nearshoring options for critical components and consumables to reduce exposure to sudden trade policy shifts. Simultaneously, accelerate investments in diagnostics and predictive analytics that enable earlier intervention, as earlier detection frequently leads to less invasive treatment needs and better outcomes. Clinical teams and manufacturers should co-design training and implementation services to reduce barriers to adoption of newer modalities and to ensure consistent protocol adherence across sites.

Engage payers and health systems early to demonstrate real-world performance and to construct reimbursement pathways that reflect value over time rather than episodic cost. Invest in modular product designs and scalable service models that can be adapted across hospitals, specialty clinics, and ambulatory surgical centers to capture diversified demand. Finally, develop clear communication strategies about supply assurance and contingency planning to reassure procurement teams and clinicians during periods of policy-driven market uncertainty. These combined actions will position organizations to respond nimbly to shifting regulatory, commercial, and clinical conditions.

A rigorous methodological framework combining clinician interviews, literature synthesis, regulatory review, and scenario analysis to ensure robust insights

The research methodology underpinning this analysis combines a multi-pronged approach to ensure robustness and relevance. Primary research included structured interviews with clinicians, procurement leaders, and industry executives to capture real-world practice patterns, procurement constraints, and adoption barriers. Secondary research synthesized peer-reviewed clinical literature, guideline publications, device regulatory filings, and publicly available policy documents to map the evidence base and to identify recent shifts in practice. Data triangulation techniques were used to reconcile differences across sources and to validate emerging themes.

Analytical methods included scenario analysis to assess potential supply chain and policy outcomes, qualitative coding of interview transcripts to surface recurring operational challenges, and comparative assessments of modality features and workflows. Limitations are acknowledged: the analysis relies on available clinical studies and expert opinion, which may evolve as new trials and regulatory decisions are published. To mitigate these limitations, the research integrated diverse stakeholder perspectives and prioritized findings with multi-source corroboration to present actionable, evidence-aligned insights.

A concise conclusion synthesizing the strategic imperatives, cross-sector responsibilities, and operational priorities essential for advancing AKI care

In conclusion, acute kidney injury treatment is at an inflection point driven by technological advances, shifting care models, and heightened attention to supply chain and policy risks. The interplay between modalities such as continuous renal replacement therapy and evolving pharmacological and supportive care strategies requires coordinated responses from clinicians, manufacturers, and payers. Regional and segmentation nuances matter: different patient cohorts and care settings demand tailored solutions, and trade policy developments can materially affect procurement and availability of critical supplies. The organizations best positioned for success will be those that combine robust clinical evidence, resilient operations, and flexible commercial strategies.

Sustained progress will depend on cross-sector collaboration: clinicians adopting standardized pathways, manufacturers delivering integrated and service-oriented offerings, and health systems enabling reimbursement structures that recognize long-term value. By aligning innovation with pragmatic implementation plans and supply assurance measures, stakeholders can reduce the clinical and economic burden of acute kidney injury while improving patient outcomes across diverse care environments.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of artificial intelligence algorithms for early detection of acute kidney injury in hospitalized patients
• 5.2. Emergence of biomarker-guided personalized therapy protocols to reduce acute kidney injury risk in surgery patients
• 5.3. Shift toward point-of-care diagnostic devices for rapid renal function assessment in critical care settings
• 5.4. Development of novel renal replacement therapies with enhanced biocompatibility and reduced complications in ICU care
• 5.5. Rising investment in cell-based regenerative medicine approaches targeting kidney injury repair mechanisms post-transplantation
• 5.6. Expansion of telemedicine-enabled patient monitoring platforms for early intervention in acute kidney injury management
• 5.7. Growing adoption of SGLT2 inhibitors for nephroprotection and acute kidney injury prevention in diabetic patients
• 5.8. Regulatory acceleration through breakthrough therapy designations for innovative AKI treatment candidates by FDA and EMA

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Kidney Injury Treatment Market, by Treatment Type

• 8.1. Dialysis
  • 8.1.1. Continuous Renal Replacement Therapy (CRRT)
  • 8.1.2. Intermittent Hemodialysis
  • 8.1.3. Sustained Low-Efficiency Dialysis (SLED)
• 8.2. Pharmacological Treatment
  • 8.2.1. Antibiotics
  • 8.2.2. Diuretics
  • 8.2.3. Pain Management Drugs
  • 8.2.4. Rehydration Drugs
• 8.3. Supportive Care
  • 8.3.1. Dietary Management
  • 8.3.2. Fluid Management

9. Acute Kidney Injury Treatment Market, by AKI Type

• 9.1. Intrinsic Renal Acute Kidney Injury
• 9.2. Post-renal Acute Kidney Injury
• 9.3. Pre-renal Acute Kidney Injury

10. Acute Kidney Injury Treatment Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Hospitals
• 10.3. Specialty Clinics

11. Acute Kidney Injury Treatment Market, by Patient Demographics

• 11.1. Adult Patients
• 11.2. Geriatric Patients
• 11.3. Pediatric Patients

12. Acute Kidney Injury Treatment Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Acute Kidney Injury Treatment Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Acute Kidney Injury Treatment Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Abbott Laboratories
  • 15.3.2. Alloksys Life Sciences B.V.
  • 15.3.3. Amgen Inc.
  • 15.3.4. Asahi Kasei Medical Co., Ltd.
  • 15.3.5. Astellas Pharma Inc.
  • 15.3.6. B. Braun Melsungen AG
  • 15.3.7. Baxter International, Inc.
  • 15.3.8. Bayer AG
  • 15.3.9. bioMerieux SA
  • 15.3.10. CardioRenal Systems, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. ACUTE KIDNEY INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. ACUTE KIDNEY INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ACUTE KIDNEY INJURY TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 148. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 149. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 151. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
• TABLE 153. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
• TABLE 154. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
• TABLE 163. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 166. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 167. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
• TABLE 168. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
• TABLE 169. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
• TABLE 170. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
• TABLE 179. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 182. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 183. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
• TABLE 184. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
• TABLE 189. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
• TABLE 190. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
• TABLE 227. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 230. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 231. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
• TABLE 232. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
• TABLE 233. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
• TABLE 234. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
• TABLE 235. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
• TABLE 236. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
• TABLE 237. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
• TABLE 238. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
• TABLE 239. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 240. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 241. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
• TABLE 242. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
• TABLE 243. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 244. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 245. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 246. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 247. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
• TABLE 248. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
• TABLE 249. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
• TABLE 250. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
• TABLE 251. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
• TABLE 252. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
• TABLE 253. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
• TABLE 254. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
• TABLE 255. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 256. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 257. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
• TABLE 258. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
• TABLE 259. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 260. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 261. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 262. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 263. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
• TABLE 264. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
• TABLE 265. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
• TABLE 266. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
• TABLE 267. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
• TABLE 268. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
• TABLE 269. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
• TABLE 270. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
• TABLE 271. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 272. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 273. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
• TABLE 274. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
• TABLE 275. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 276. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 277. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 278. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 279. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 280. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 281. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
• TABLE 282. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
• TABLE 283. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
• TABLE 284. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
• TABLE 285. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
• TABLE 286. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
• TABLE 287. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
• TABLE 288. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
• TABLE 289. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 290. ASEAN ACUTE KIDNEY